SCYNEXIS Inc NASDAQ:SCYX:
SCYNEXIS INITIATES PHASE 1 STUDY OF SCY-770, A NOVEL AMPK ACTIVATOR FOR THE TREATMENT OF AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD)
SCYNEXIS - PHASE 2 STUDY IN ADPKD EXPECTED TO BEGIN IN Q4 2026
SCYNEXIS - TOPLINE PHASE 1 DATA EXPECTED IN Q3 2026